Search This Blog

Friday, August 14, 2026

'Climb Bio and Mabworks begin dosing in Phase 2 trial for kidney disease in China'

 

Climb Bio, Inc. (NASDAQ:CLYM) announced that Beijing Mabworks Biotech Co., Ltd. has begun dosing the first patient.

Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)